9 hrs ago
Horizon Pharma Announces the Appointment of H. Thomas Watkins to Its Board of Directors
Additionally, Jean-Francois Formela, M.D. has resigned from the Horizon board of directors.
Scheer Partners, Inc. Hired By To Lease 9410 Key West Avenue In Rockville
Scheer Partners, the leading provider of fully integrated commercial real estate services for the health science industry in the Washington and Baltimore metropolitan areas, announced today that Chevy Chase-based DANAC, LLC has engaged the Rockville-based company to market a full building containing 48,270 square feet of contiguous laboratory, ... (more)
Bad news for GlaxoSmithKline's darapladib, a drug key to Human Genome Sciences buyout
GlaxoSmithKline this weekend illustrated disappointing results of a late-stage trial for heart drug darapladib, one of the three major assets the British pharma company scooped up in its $3 billion acquisition of Rockville's Human Genome Sciences two years ago.
Study shows Glaxo heart drug which failed trial has potential benefit
An experimental heart drug being developed by GlaxoSmithKline, which failed the main goal of a Phase III study of patients with chronic but well-treated heart disease, showed signs of potential benefit, the trial's co-leader said Sunday.
WellDoc Names Biotech Veteran as President
WellDoc , developers of the first FDA-cleared, mobile prescription therapy, BlueStar TM, announced today that Kevin P. McRaith has joined the Company as President.